Author:
Undevia Samir D.,Innocenti Federico,Ramirez Jacqueline,House Larry,Desai Apurva A.,Skoog Linda A.,Singh Deepti A.,Karrison Theodore,Kindler Hedy L.,Ratain Mark J.
Reference22 articles.
1. Preclinical antitumor activity of XK469 (NSC 656889);LoRusso;Invest New Drugs,1999
2. Wiegand RA, Doyle TD, Grieshaber CK et al. Normal-phase separation of XK469 enantiomers (R:NSC-698215, S:NSC-698216) applied to preclinical pharmacology. In: Proceedings of the AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics; 1999. Washington, DC [Abstract 542].
3. Chiral high-performance liquid chromatographic analysis of the enantiomers of XK469, a new antitumor agent, in plasma and urine;Zheng;J Pharm Biomed Anal,2002
4. Chiral pharmacokinetics and inversion of enantiomers of a new quinoxaline topoisomerase IIβ poison in the rat;Zheng;Drug Metab Dispos,2002
5. XK469, a selective topoisomerase IIβ poison;Gao;Proc Natl Acad Sci USA,1999
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献